Literature DB >> 17911519

Comparison of transcatheter intraarterial perfusion MR imaging and fluorescent microsphere perfusion measurements during transcatheter arterial embolization of rabbit liver tumors.

Sumeet Virmani1, Dingxin Wang, Kathleen R Harris, Robert K Ryu, Kent T Sato, Robert J Lewandowski, Albert A Nemcek, Barbara Szolc-Kowalska, Gayle Woloschak, Riad Salem, Andrew C Larson, Reed A Omary.   

Abstract

PURPOSE: Transcatheter intraarterial perfusion (TRIP) magnetic resonance (MR) imaging is clinically used in the interventional MR imaging setting to verify distribution of injected embolic or chemoembolic material during liver-directed transcatheter therapies and to monitor reductions in perfusion. The accuracy of this technique remains unknown. In the present study, rabbit VX2 liver tumors were used to test the hypothesis that TRIP MR imaging accurately measures changes in tumor perfusion during transcatheter arterial embolization (TAE), with injection of fluorescent microspheres used as the gold-standard technique.
MATERIALS AND METHODS: Five New Zealand White rabbits were used for this study (two donor rabbits and three with VX2 liver tumors). In three rabbits with implanted VX2 liver tumors, catheters were superselectively placed under digital subtraction angiographic guidance into the left hepatic artery supplying the targeted tumor. Fluorescent microspheres were injected into each rabbit's left ventricle before and after TAE. TRIP MR images were obtained at baseline and after embolizations for all rabbits with intraarterial injections of 2.5% gadopentetate dimeglumine solution. Linear regression was used to compare relative reductions in tumor perfusion between TRIP MR imaging and fluorescent microspheres. Results were considered statistically significant at a P value less than .05.
RESULTS: There was good correlation between TRIP MR imaging and fluorescent microsphere measurements of reduction in tumor perfusion (r = 0.722, P < .012).
CONCLUSIONS: TRIP MR imaging provides accurate semiquantitative measurement of perfusion reduction during TAE in rabbit liver tumors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17911519     DOI: 10.1016/j.jvir.2007.07.008

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  11 in total

1.  Four-dimensional transcatheter intra-arterial perfusion MR imaging before and after uterine artery embolization in the rabbit VX2 tumor model.

Authors:  Johnathan C Chung; Dingxin Wang; Robert J Lewandowski; Richard Tang; Howard B Chrisman; Robert L Vogelzang; Gayle E Woloschak; Andrew C Larson; Reed A Omary; Robert K Ryu
Journal:  J Magn Reson Imaging       Date:  2010-05       Impact factor: 4.813

2.  Quantitative 4D transcatheter intraarterial perfusion MRI for monitoring chemoembolization of hepatocellular carcinoma.

Authors:  Dingxin Wang; Brian Jin; Robert J Lewandowski; Robert K Ryu; Kent T Sato; Mary F Mulcahy; Laura M Kulik; Frank H Miller; Riad Salem; Debiao Li; Reed A Omary; Andrew C Larson
Journal:  J Magn Reson Imaging       Date:  2010-05       Impact factor: 4.813

3.  Radiopaque drug-eluting beads for transcatheter embolotherapy: experimental study of drug penetration and coverage in swine.

Authors:  Matthew R Dreher; Karun V Sharma; David L Woods; Goutham Reddy; Yiqing Tang; William F Pritchard; Oscar A Chiesa; John W Karanian; Juan A Esparza; Danielle Donahue; Elliot B Levy; Sean L Willis; Andrew L Lewis; Bradford J Wood
Journal:  J Vasc Interv Radiol       Date:  2011-12-16       Impact factor: 3.464

4.  Four-dimensional transcatheter intraarterial perfusion (TRIP)-MRI for monitoring liver tumor embolization in VX2 rabbits.

Authors:  Dingxin Wang; Sumeet Virmani; Richard Tang; Barbara Szolc-Kowalska; Gayle Woloschak; Reed A Omary; Andrew C Larson
Journal:  Magn Reson Med       Date:  2008-10       Impact factor: 4.668

5.  Four-dimensional transcatheter intraarterial perfusion MR imaging for monitoring chemoembolization of hepatocellular carcinoma: preliminary results.

Authors:  Ron C Gaba; Dingxin Wang; Robert J Lewandowski; Robert K Ryu; Kent T Sato; Laura M Kulik; Mary F Mulcahy; Andrew C Larson; Riad Salem; Reed A Omary
Journal:  J Vasc Interv Radiol       Date:  2008-09-25       Impact factor: 3.464

6.  MRI-monitored transcatheter intra-arterial delivery of SPIO-labeled natural killer cells to hepatocellular carcinoma: preclinical studies in a rodent model.

Authors:  Alexander Y Sheu; Zhuoli Zhang; Reed A Omary; Andrew C Larson
Journal:  Invest Radiol       Date:  2013-06       Impact factor: 6.016

7.  Rabbit hepatic arterial anatomy variations: implications on experimental design.

Authors:  Alda L Tam; Marites P Melancon; Joe Ensor; Yang Liu; Katherine Dixon; Amanda McWatters; Sanjay Gupta
Journal:  Acta Radiol       Date:  2013-11-29       Impact factor: 1.990

8.  Comparison of hypoxia-inducible factor-1alpha expression before and after transcatheter arterial embolization in rabbit VX2 liver tumors.

Authors:  Sumeet Virmani; Thomas K Rhee; Robert K Ryu; Kent T Sato; Robert J Lewandowski; Mary F Mulcahy; Laura M Kulik; Barbara Szolc-Kowalska; Gayle E Woloschak; Guang-Yu Yang; Riad Salem; Andrew C Larson; Reed A Omary
Journal:  J Vasc Interv Radiol       Date:  2008-10       Impact factor: 3.464

9.  Considerations for implantation site of VX2 carcinoma into rabbit liver.

Authors:  Kwang-Hun Lee; Eleni Liapi; Manon Buijs; Josephina Vossen; Kelvin Hong; Christos Georgiades; Jean-Francois H Geschwind
Journal:  J Vasc Interv Radiol       Date:  2008-11-22       Impact factor: 3.464

10.  Distribution of Iron Oxide Core-Titanium Dioxide Shell Nanoparticles in VX2 Tumor Bearing Rabbits Introduced by Two Different Delivery Modalities.

Authors:  Tamer Refaat; Derek West; Samar El Achy; Vamsi Parimi; Jasmine May; Lun Xin; Kathleen R Harris; William Liu; Michael Beau Wanzer; Lydia Finney; Evan Maxey; Stefan Vogt; Reed A Omary; Daniele Procissi; Andrew C Larson; Tatjana Paunesku; Gayle E Woloschak
Journal:  Nanomaterials (Basel)       Date:  2016-08-03       Impact factor: 5.076

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.